Dr. Yu Han 韩宇
Chief Physician
Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and molecular targeted therapy for digestive tract tumors. Research interests include EGFR signaling pathways and predicting efficacy of molecular targeted drugs.
Dr. Han holds a PhD in Oncology. The doctor has led three provincial research projects and published over ten articles in domestic core journals and two SCI-indexed papers. Awards include the Harbin Medical University New Technology Third Prize (2003), Military Academy of Medical Sciences Outstanding Doctoral Student (2006), and Heilongjiang Provincial Medical and Health New Technology Second Prize (2008).
Name order: in Chinese the family name comes first (Han Yu). Papers usually list the name as Yu Han or Han Y.
Selected publications
19 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): A composite biomarker based on early dynamic changes in lactate dehydrogenase and PD-L1 expression enhances outcome prediction for immunochemotherapy in HER2-negative advanced gastric cancer. PubMed 41766893
- Medicine (Baltimore), 2025 (senior author): Metabolic and aging related gene risk score for therapeutic stratification and precision oncology in gastric cancer. PubMed 41431056
- J Cancer, 2022 (senior author): LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways. PubMed 34976187
- Cancer Cell Int, 2018 (senior author): Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer. PubMed 30377411
- Mol Carcinog, 2018 (senior author): Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. PubMed 29637613
- Oncotarget, 2017 (senior author): siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. PubMed 28881753
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion